Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UKT7

UPID:
FBXL3_HUMAN

ALTERNATIVE NAMES:
F-box and leucine-rich repeat protein 3A; F-box/LRR-repeat protein 3A

ALTERNATIVE UPACC:
Q9UKT7; B2RB04; Q9P122

BACKGROUND:
The F-box/LRR-repeat protein 3, known for its alternative names F-box and leucine-rich repeat protein 3A, is integral to circadian rhythm regulation. By serving as a component of the SCF(FBXL3) E3 ubiquitin ligase complex, it ensures the robustness and accuracy of circadian oscillations through the targeted degradation of CRY1 and CRY2.

THERAPEUTIC SIGNIFICANCE:
The exploration of F-box/LRR-repeat protein 3's function offers promising avenues for developing treatments for Intellectual developmental disorder with short stature, facial anomalies, and speech defects. The association of gene variants with this condition underscores the protein's potential impact on intellectual and physical development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.